Contributions
Type: Publication Only
Background
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). But none have been directly compared in a prospective randomized trial.
Aims
In this report, we want to evaluate outcome of our adult ALL patients treated with BFM-like and Hyper-CVAD protocols retrospectively and also evaluate the feasibility of BFM protocol in adult patients in case of efficacy and tolerability.
Methods
.In this study, we want to evaluate outcome of our 50 adult ALL patients treated with Berlin-Frankfurt-Munster (BFM) (20 patients) and Hyper-CVAD (30 patients) protocols between march 2006 and october 2012.
Results
The median age was 25 years in BFM, 30.5 years in Hyper-CVAD group with M/F ratio 15/5 and 17/13 respectively. 45% of patients in BFM group and 30.3% of patients in Hyper-CVAD group were under age of 25. The majority of cases were B cell in origin (80% in BFM, 70% Hyper-CVAD group). Complete remission after induction therapy was achieved in 95% and 96% of the patients, respectively. Median follow-up time was 37 months. Five-year survival rate was higher in BFM group with respect to Hyper-CVAD group (59% x 34%). There were also no complication which can cause a delay during Hyper-CVAD regimen. Both chemotherapy were well tolerated. None of patients died due to drug related toxicity. Only mild liver enzyme elevations were seen as toxicity in BFM which didn’t cause any delay in therapy.
Summary
BFM regimen seems to be feasible for adult patients with ALL in case of tolerability and efficacy especially in young adults.
Keyword(s): Acute lymphoblastic leukemia, Chemotherapy, Hyper-CVAD
Type: Publication Only
Background
Multiple induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). But none have been directly compared in a prospective randomized trial.
Aims
In this report, we want to evaluate outcome of our adult ALL patients treated with BFM-like and Hyper-CVAD protocols retrospectively and also evaluate the feasibility of BFM protocol in adult patients in case of efficacy and tolerability.
Methods
.In this study, we want to evaluate outcome of our 50 adult ALL patients treated with Berlin-Frankfurt-Munster (BFM) (20 patients) and Hyper-CVAD (30 patients) protocols between march 2006 and october 2012.
Results
The median age was 25 years in BFM, 30.5 years in Hyper-CVAD group with M/F ratio 15/5 and 17/13 respectively. 45% of patients in BFM group and 30.3% of patients in Hyper-CVAD group were under age of 25. The majority of cases were B cell in origin (80% in BFM, 70% Hyper-CVAD group). Complete remission after induction therapy was achieved in 95% and 96% of the patients, respectively. Median follow-up time was 37 months. Five-year survival rate was higher in BFM group with respect to Hyper-CVAD group (59% x 34%). There were also no complication which can cause a delay during Hyper-CVAD regimen. Both chemotherapy were well tolerated. None of patients died due to drug related toxicity. Only mild liver enzyme elevations were seen as toxicity in BFM which didn’t cause any delay in therapy.
Summary
BFM regimen seems to be feasible for adult patients with ALL in case of tolerability and efficacy especially in young adults.
Keyword(s): Acute lymphoblastic leukemia, Chemotherapy, Hyper-CVAD